Effective management of schizophrenia (SZ) requires long-term treatment with
antipsychotics (APs) to prevent clinical relapse, attain remission and improve patients' …

C ompared to the general population, women with histories of psychotic and affective
illnesses are at increased risk of psychiatric symptoms during pregnancy. 1, 2 Although …

Our study aimed to examine pregnancy, neonatal and psychosocial outcomes for women
treated with LAIs at tertiary maternity hospital. A retrospective review of all women who were …

Introduction: Pregnant women and fetuses are more likely than ever to be exposed to
antipsychotic drugs (APs) during pregnancy and postpartum period. Second-generation APs …

Purpose of review Antipsychotics are frequently prescribed to women of childbearing age
and are increasingly prescribed during pregnancy. A small, but growing, body of research …

Background Long-acting injectable antipsychotic medications (LAIs) are an evidence-based
treatment option for people with severe mental illness. While women with severe mental …

Objective: The objective of this study was to describe the safety, efficacy, and potential role
in therapy of once in 6 months paliperidone palmitate formulation (PP6M; Invega Hafyera) …

Background Long-acting injectable (LAI) antipsychotics for psychotic disorders provide
advantages in treatment compliance, but data on their use in pregnancy are very limited. We …

Aims Paliperidone palmitate 3-month (PP3M) represents a new long-acting injectable
antipsychotic therapeutic option. This review aims: 1) to summarize available data relating to …

Abstract Purpose of Review The perinatal period is a time of increased vulnerability for
people with bipolar disorder (BD). The purpose of this review is to provide an update of the …